• Our Company
  • About us
  • About Xanamem^® (emestedastat)
  • Xanamem® Pipeline
  • Our Team
  • Recent Annual Reports
  • Our Strategic Priorities
  • Corporate Governance
• Xanamem^® (emestedastat)
  • Mechanism of Action
  • The Cortisol Hypothesis
  • Publications
• Clinical Trials
  • Clinical Development Pipeline
    • Cognitive Impairment in early Alzheimer’s Disease
    • Cognitive Impairment in MDD
    • Anxiety, sleep & behavioral problems in Fragile X Syndrome
  • Patient Portal
  • The XanaMIA Phase 2b/3 Alzheimer’s Trial
  • Publications
• Investor Centre
• News
• Contact Us